Qure.ai

Qure.ai is a healthcare technology company that develops artificial intelligence solutions for medical imaging, clinical decision support, and care coordination. Founded in 2016, the company uses deep learning to help healthcare professionals identify diseases, interpret medical scans, prioritize urgent cases, and coordinate patient care. Its technology is designed to support radiologists, physicians, hospitals, diagnostic centres, public health programmes, and other healthcare organizations that need to improve the speed and efficiency of medical services. Qure.ai focuses on making healthcare more accessible and equitable, particularly in settings where access to specialist expertise and diagnostic resources may be limited.

The company develops AI-powered software for interpreting different types of medical images, including chest X-rays, head CT scans, chest CT scans, and musculoskeletal X-rays. Rather than replacing healthcare professionals, these tools are designed to assist clinical teams by highlighting possible abnormalities, providing measurements, generating structured findings, and helping users identify examinations that may require urgent attention. The technology can be incorporated into existing radiology workflows, allowing healthcare organizations to use AI assistance without necessarily replacing their established imaging systems.

One of Qure.ai’s best-known products is qXR, an AI-powered chest X-ray interpretation solution. It analyses chest radiographs and identifies abnormalities involving the lungs, pleura, mediastinum, bones, diaphragm, and heart. The software can highlight suspicious regions on an image and provide findings that help radiologists review examinations more efficiently. Its capabilities include identifying signs associated with conditions such as tuberculosis, lung cancer, and other chest abnormalities. It can also help identify potentially important findings that might otherwise require additional review.

qXR is designed to support both routine radiology reporting and large-scale screening programmes. In busy hospitals and diagnostic centres, it can help organize imaging worklists by identifying examinations that appear normal and highlighting cases with potentially significant findings. This can assist radiology departments in managing high examination volumes and directing attention towards cases that may need faster assessment. The software also provides pre-read assistance and AI-generated visual overlays, helping clinicians locate areas of interest while reviewing the original images. Qure.ai states that qXR can process supported chest X-rays in less than 20 seconds, although actual performance may depend on the deployment environment and workflow.

Another important solution is qER, which focuses on head CT interpretation and neurocritical care. It analyses non-contrast head CT scans to identify findings associated with intracranial haemorrhage, stroke, traumatic brain injury, and other neurological abnormalities. The software can identify and highlight suspected findings, provide measurements, and help prioritize scans for clinical review. This is particularly relevant in emergency departments, where delays in recognizing serious neurological conditions can affect the time available for clinical intervention.

qER is also designed to support communication and coordination among healthcare professionals involved in stroke care. When a potentially urgent finding is identified, the connected workflow can help notify relevant members of the care team and support the transfer of information between facilities. This is useful in healthcare networks where smaller hospitals may need to coordinate with larger specialist centres. Qure.ai’s stroke-care approach combines imaging analysis with communication and referral workflows to help clinical teams organize patient assessment and treatment more efficiently. The software remains a clinical support tool, and medical professionals are responsible for interpreting findings and making treatment decisions.

For lung cancer detection and follow-up, Qure.ai provides qCT, a solution designed to analyse chest CT scans and support lung nodule assessment. Its capabilities include identifying and measuring pulmonary nodules, supporting volumetric analysis, and helping clinicians monitor changes in nodules over time. This is important because lung nodules may require follow-up imaging and clinical assessment to determine whether they are stable or show signs that need further investigation. By providing measurements and structured information, qCT can assist radiologists and pulmonologists with the review and monitoring process.

Qure.ai’s lung health solutions also support a broader pathway that connects initial detection with follow-up management. Its chest X-ray and CT tools can contribute to identifying patients who may need additional imaging or clinical assessment. The company’s approach is intended to help healthcare organizations connect imaging findings with subsequent steps in the patient’s care journey, rather than treating scan interpretation as an isolated activity. This can be relevant to hospitals and screening programmes working to improve early identification and monitoring of lung conditions.

The company also offers qMSK, an AI assistant for musculoskeletal X-ray interpretation. It is designed to help identify possible fractures and other findings in X-rays involving different parts of the musculoskeletal system. The product supports multiple anatomical regions and views, with visual markers that help clinicians locate areas of interest. It can also assist with worklist prioritization and the review of examinations in emergency departments and teleradiology environments. Its ability to assess multiple views may help reduce the risk of overlooking additional fractures during image review. As with the company’s other products, its findings are intended to support, rather than replace, professional clinical assessment.

Qure.ai provides qTrack, a platform for screening programme management, case tracking, and care coordination. It is particularly relevant to tuberculosis screening and other public health initiatives that involve large numbers of people and multiple healthcare facilities. qTrack helps organizations manage the stages between initial screening, diagnostic confirmation, notification, and follow-up. It can organize patient information, monitor case progress, and provide dashboards that help programme teams understand how screening activities are progressing. By connecting imaging results with case-management workflows, the platform can help reduce administrative gaps and make it easier to monitor patients who require further assessment.

The company has also introduced AIRA, an AI-powered care delivery platform designed to support healthcare workers and health systems beyond radiology. AIRA focuses on digitizing routine healthcare information, supporting protocol-guided consultations, organizing patient records, and improving follow-up. Its features include converting voice conversations and handwritten information into structured records, digitizing paper forms and registers, and helping healthcare teams maintain continuity across patient interactions. It is intended to work with existing health infrastructure and can be configured for local guidelines, languages, and workflows. Qure.ai describes AIRA as a way to turn information collected during routine care into more useful data for frontline workers and health programme administrators.

AIRA is also designed for healthcare programmes operating across facilities and community settings. It can support follow-up reminders, patient guidance, documentation, and the identification of cases that may require additional attention. For health system managers, the platform can provide information about programme activity, service gaps, and patterns that may need intervention. These capabilities make it relevant to public health organizations that need to coordinate services across different locations and maintain more consistent records. Its use in local programmes demonstrates Qure.ai’s interest in applying AI to broader healthcare delivery challenges, not only medical image interpretation.

Qure.ai’s wider product ecosystem includes the Qure.ai application, which provides access to supported imaging workflows through web and mobile environments. The application can display medical images and AI-generated findings, allowing authorized healthcare professionals to review information and share it with other members of a care team. It is designed to work with medical imaging systems and supports workflows involving DICOM studies. The company’s documentation describes connections with Picture Archiving and Communication Systems (PACS) and imaging modalities, helping organizations transfer studies for processing and view the resulting reports.

Integration is an important part of Qure.ai’s approach. Healthcare organizations generally need imaging software to work alongside existing PACS, electronic medical records, dictation tools, and reporting systems. Qure.ai describes its solutions as capable of integrating with these environments and supporting different deployment requirements. Depending on the product and implementation, deployments may use cloud-based or on-premises infrastructure. The company also provides API documentation for its platform, enabling technical teams to explore programmatic access and integration workflows. The exact integration configuration depends on the healthcare organization’s systems, security requirements, and contracted solution.

Qure.ai places importance on clinical validation, regulatory compliance, and evidence supporting the use of its products. The company reports that several of its solutions have received regulatory clearances, including US FDA 510(k) clearances for specified products and indications. These clearances apply to particular software versions and intended uses, rather than automatically covering every product or feature offered by the company. Healthcare organizations should therefore confirm the regulatory status and permitted use of the exact product in their country before implementation.

The company serves different types of healthcare organizations, including hospitals, imaging centres, teleradiology providers, public health programmes, government health departments, and organizations involved in pharmaceutical and medical device research. Its solutions can be used in emergency care, radiology reporting, tuberculosis screening, lung cancer pathways, stroke management, and musculoskeletal imaging. Qure.ai also works with healthcare partners and organizations involved in expanding access to diagnostic services. Its global deployments demonstrate that the products are intended for use in different healthcare environments, including regions where specialist resources may be limited.

Qure.ai has developed partnerships across healthcare, technology, and life sciences. Its collaborations have included organizations such as Microsoft, Medtronic, and AstraZeneca, supporting different applications of AI in medical imaging, screening, and care delivery. These partnerships illustrate how the company’s technology can be incorporated into wider healthcare initiatives, although the availability of a particular product or partnership-supported service may vary by market.

A key strength of Qure.ai is its focus on specific clinical workflows rather than offering a general-purpose AI assistant. Its products address defined medical imaging and healthcare coordination needs, with tools for detecting abnormalities, prioritizing examinations, supporting follow-up, and organizing clinical information. This specialization makes the platform relevant to healthcare providers that want to introduce AI assistance into established diagnostic and patient-management processes.

However, Qure.ai is not a general-purpose medical application for consumers, nor is it a substitute for a hospital’s complete radiology information system or the professional judgment of a clinician. Its products require appropriate medical imaging equipment, compatible systems, trained users, and suitable clinical workflows. Healthcare organizations must also assess regulatory requirements, data protection, infrastructure, and the suitability of each product for their intended patient population. The company offers a specialized set of tools, so the value of an implementation depends on whether the available products match the organization’s clinical and operational needs.

Overall, Qure.ai is a specialized healthcare AI provider with a broad portfolio covering medical imaging interpretation, lung health, neurological emergencies, musculoskeletal imaging, screening programme management, and digital care delivery. Its combination of products such as qXR, qER, qCT, qMSK, qTrack, and AIRA makes it relevant to hospitals, diagnostic centres, public health programmes, and healthcare networks seeking to improve diagnostic workflows and patient follow-up. Its integration options, regulatory work, and international deployments make it an established participant in the healthcare AI sector, while its enterprise-focused approach means that organizations generally need to discuss their requirements directly with the company.

Pricing

Qure.ai uses a business-to-business pricing approach for its healthcare AI products. The cost of implementation depends on the selected solution, number of scans, deployment requirements, healthcare organization, and level of support required. Its commercial arrangements may be structured around scan volumes, subscription periods, or customized deployment agreements. The company does not publish a universal price list covering all its products.

Review

Qure.ai offers a specialized collection of AI tools for medical imaging and healthcare coordination. Its strongest feature is the way its products address specific clinical needs, including chest X-ray interpretation, head CT analysis, lung nodule assessment, fracture detection, and screening programme management. This makes the platform useful to healthcare organizations that want to introduce AI assistance into established clinical workflows.

The range of products is another advantage. qXR, qER, qCT, and qMSK cover different imaging requirements, while qTrack and AIRA extend the platform into patient follow-up, programme management, and healthcare documentation. This gives organizations the opportunity to use different solutions across connected care pathways instead of relying on a single-purpose imaging tool.

Integration and deployment flexibility are also important strengths. Qure.ai supports workflows involving PACS, medical imaging systems, reporting environments, and other healthcare infrastructure. Its cloud and on-premises deployment options can help organizations assess which approach is appropriate for their technical and operational requirements. The availability of API documentation is also useful for teams exploring custom integrations.

However, Qure.ai is primarily designed for healthcare organizations rather than individual consumers. Its products require suitable medical systems, trained clinical users, and implementation planning. Pricing is not fully transparent because costs depend on the solution and deployment agreement. Organizations may also need to consider infrastructure, integration, regulatory compliance, and ongoing support expenses.

Another consideration is that regulatory clearance and intended use differ across products and indications. Healthcare providers should verify the status of the specific product and software version they plan to use. AI-generated findings should be reviewed within the appropriate clinical workflow and should not be treated as a replacement for professional diagnosis.

Overall, Qure.ai is a strong option for hospitals, diagnostic centres, and public health programmes looking for specialized AI support across medical imaging and care coordination. Its product range and integration capabilities are valuable, although its enterprise-oriented pricing and implementation requirements may make it less suitable for small organizations seeking a simple, self-service tool.